Literature DB >> 10602694

Properties of known drugs. 2. Side chains.

G W Bemis1, M A Murcko.   

Abstract

We continue our study of the common features present in drug molecules by looking in detail at drug side chains. Using shape description methods, we divide a database of commercially available drugs into a list of common drug side chains. On the basis of the atom pair shape descriptor (taking into account atom type, hybridization, and bond order), there are 1,246 different side chains among the 5,090 compounds analyzed. The average number of side chains per molecule is 4, and the average number of heavy atoms per side chain is 2. If we ignore the carbonyl side chain, then there are approximately 15,000 occurrences of side chains. Of these 15,000 approximately 11,000 are from the "top 20" group of side chains. This suggests that the diversity that side chains provide to drug molecules is quite low. We discuss ways that this work could be used to provide guidance for molecular design efforts.

Mesh:

Substances:

Year:  1999        PMID: 10602694     DOI: 10.1021/jm9903996

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

Review 1.  An overview of the diversity represented in commercially-available databases.

Authors:  Mary P Bradley
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

Review 2.  An overview of the diversity represented in commercially-available databases.

Authors:  Mary P Bradley
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

Review 3.  The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design.

Authors:  Christian R Schubert; Collin M Stultz
Journal:  J Comput Aided Mol Des       Date:  2009-06-09       Impact factor: 3.686

4.  Lessons for fragment library design: analysis of output from multiple screening campaigns.

Authors:  I-Jen Chen; Roderick E Hubbard
Journal:  J Comput Aided Mol Des       Date:  2009-06-03       Impact factor: 3.686

5.  Towards a new age of virtual ADME/TOX and multidimensional drug discovery.

Authors:  Sean Ekins; Bruno Boulanger; Peter W Swaan; Maggie A Z Hupcey
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

6.  Screening of benzamidine-based thrombin inhibitors via a linear interaction energy in continuum electrostatics model.

Authors:  Orazio Nicolotti; Ilenia Giangreco; Teresa Fabiola Miscioscia; Marino Convertino; Francesco Leonetti; Leonardo Pisani; Angelo Carotti
Journal:  J Comput Aided Mol Des       Date:  2010-02-11       Impact factor: 3.686

Review 7.  The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins.

Authors:  Shohei Koide; Sachdev S Sidhu
Journal:  ACS Chem Biol       Date:  2009-05-15       Impact factor: 5.100

8.  Discovery of fragment molecules that bind the human peroxiredoxin 5 active site.

Authors:  Sarah Barelier; Dominique Linard; Julien Pons; André Clippe; Bernard Knoops; Jean-Marc Lancelin; Isabelle Krimm
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

9.  The pK(a) Distribution of Drugs: Application to Drug Discovery.

Authors:  David T Manallack
Journal:  Perspect Medicin Chem       Date:  2007-09-17

10.  Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.

Authors:  Lindsay B Tulloch; Viviane P Martini; Jorge Iulek; Judith K Huggan; Jeong Hwan Lee; Colin L Gibson; Terry K Smith; Colin J Suckling; William N Hunter
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.